Total Payments
$404,014
2024 Payments
$12,342
Companies
21
Transactions
251
Medicare Patients
134
Medicare Billing
$14,002
Payment Breakdown by Category
Consulting$232,667 (57.6%)
Other$89,330 (22.1%)
Travel$47,653 (11.8%)
Research$28,669 (7.1%)
Food & Beverage$5,695 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $232,667 | 54 | 57.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $84,380 | 10 | 20.9% |
| Travel and Lodging | $47,653 | 77 | 11.8% |
| Unspecified | $28,669 | 18 | 7.1% |
| Food and Beverage | $5,695 | 91 | 1.4% |
| Honoraria | $4,950 | 1 | 1.2% |
Payments by Type
General
$375,345
233 transactions
Research
$28,669
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $81,864 | 48 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $79,737 | 21 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $50,318 | 38 | $0 (2017) |
| Bayer HealthCare Pharmaceuticals Inc. | $42,197 | 39 | $0 (2022) |
| Amgen Inc. | $41,312 | 20 | $0 (2024) |
| Novo Nordisk Inc | $16,617 | 7 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $15,236 | 7 | $0 (2022) |
| Pfizer Inc. | $12,420 | 7 | $0 (2020) |
| Amarin Pharma Inc. | $12,369 | 20 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $11,538 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,342 | 4 | IDORSIA PHARMACEUTICALS US INC ($7,080) |
| 2023 | $8,304 | 6 | Amgen Inc. ($4,760) |
| 2022 | $28,899 | 20 | Bayer HealthCare Pharmaceuticals Inc. ($16,782) |
| 2021 | $31,149 | 19 | Bayer HealthCare Pharmaceuticals Inc. ($16,644) |
| 2020 | $50,418 | 16 | Novo Nordisk Inc ($12,000) |
| 2019 | $83,755 | 64 | Janssen Scientific Affairs, LLC ($20,763) |
| 2018 | $75,241 | 33 | SANOFI-AVENTIS U.S. LLC ($48,848) |
| 2017 | $113,906 | 89 | Merck Sharp & Dohme Corporation ($50,318) |
All Payment Transactions
251 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Janssen Scientific Affairs, LLC | XARELTO (Drug) | — | Cash or cash equivalent | $1,200.00 | Research |
| Category: Cardiovascular & Metabolism | ||||||
| 09/26/2024 | IDORSIA PHARMACEUTICALS US INC | Tryvio (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,080.00 | General |
| Category: Hypertension | ||||||
| 03/22/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $2,262.00 | General |
| 02/19/2024 | Janssen Scientific Affairs, LLC | XARELTO (Drug) | — | Cash or cash equivalent | $1,800.00 | Research |
| Category: Cardiovascular & Metabolism | ||||||
| 11/10/2023 | Janssen Scientific Affairs, LLC | XARELTO (Drug) | Food and Beverage | In-kind items and services | $149.13 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/21/2023 | Janssen Scientific Affairs, LLC | XARELTO (Drug) | — | Cash or cash equivalent | $600.00 | Research |
| Study: PASCAL Research Program • Category: Cardiovascular & Metabolism | ||||||
| 04/05/2023 | Amgen Inc. | Repatha (Biological) | Consulting Fee | Cash or cash equivalent | $4,760.00 | General |
| Category: Cardiology | ||||||
| 03/05/2023 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $132.68 | General |
| 01/03/2023 | Novo Nordisk Inc | Rybelsus (Drug) | Consulting Fee | Cash or cash equivalent | $1,162.50 | General |
| Category: Diabetes | ||||||
| 01/02/2023 | Janssen Scientific Affairs, LLC | XARELTO (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 11/19/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $13,020.00 | General |
| Category: Cardio-renal | ||||||
| 11/19/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $757.20 | General |
| Category: Cardio-renal | ||||||
| 11/19/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $147.02 | General |
| Category: Cardio-renal | ||||||
| 11/19/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $114.75 | General |
| Category: Cardio-renal | ||||||
| 11/19/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $101.25 | General |
| Category: Cardio-renal | ||||||
| 11/19/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $88.50 | General |
| Category: Cardio-renal | ||||||
| 11/19/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $30.38 | General |
| Category: Cardio-renal | ||||||
| 11/19/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $30.38 | General |
| Category: Cardio-renal | ||||||
| 11/18/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $461.35 | General |
| Category: Cardio-renal | ||||||
| 11/18/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $258.33 | General |
| Category: Cardio-renal | ||||||
| 11/18/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $114.74 | General |
| Category: Cardio-renal | ||||||
| 11/18/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $78.98 | General |
| Category: Cardio-renal | ||||||
| 11/18/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $29.16 | General |
| Category: Cardio-renal | ||||||
| 11/04/2022 | Janssen Scientific Affairs, LLC | XARELTO (Drug) | Food and Beverage | In-kind items and services | $49.90 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/07/2022 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN9924-4558 | Novo Nordisk Inc | $10,875 | 4 |
| PASCAL Research Program | Janssen Scientific Affairs, LLC | $8,850 | 7 |
| NN9924-4558 | Novo Nordisk AS | $3,750 | 1 |
| Prospective Observational study of Lipid Management in Non-US, Non-Western European Patients Who Have A Recent Acute Coronary Syndrome Event | SANOFI-AVENTIS U.S. LLC | $1,250 | 1 |
| HEALTH ECONOMICS OUTCOME RESEARCH RELATED TO PRALUENT | Regeneron Pharmaceuticals, Inc. | $944.13 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 3 | 134 | 194 | $49,562 | $14,002 |
Total Patients
134
Total Services
194
Medicare Billing
$14,002
Procedure Codes
3
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 71 | 98 | $24,990 | $6,469 | 25.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 39 | 70 | $17,500 | $5,447 | 31.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 24 | 26 | $7,072 | $2,086 | 29.5% |
About Dr. Eric Peterson, M.D
Dr. Eric Peterson, M.D is a Cardiovascular Disease healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720162613.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Peterson, M.D has received a total of $404,014 in payments from pharmaceutical and medical device companies, with $12,342 received in 2024. These payments were reported across 251 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($232,667).
As a Medicare-enrolled provider, Peterson has provided services to 134 Medicare beneficiaries, totaling 194 services with total Medicare billing of $14,002. Data is available for 1 year (2020–2020), covering 3 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Dallas, TX
- Active Since 10/25/2006
- Last Updated 01/25/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1720162613
Products in Payments
- XARELTO (Drug) $82,096
- PRALUENT (Drug) $69,079
- Repatha (Biological) $39,020
- Kerendia (Drug) $30,946
- ELIQUIS (Drug) $18,988
- Vascepa (Drug) $12,369
- LEQVIO (Drug) $11,029
- PRALUENT (Biological) $10,658
- Impella (Device) $8,152
- RYBELSUS (Drug) $7,500
- Tryvio (Drug) $7,080
- ACZ885M (Biological) $6,757
- FARXIGA (Drug) $6,292
- Rybelsus (Drug) $4,913
- Non-Covered $2,480
- JARDIANCE (Drug) $2,320
- PRALUENT ALIROCUMAB INJECTION (Biological) $944.13
- MOVANTIK (Drug) $900.00
- ILARIS (Biological) $367.00
- JANUVIA (Drug) $169.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Dallas
Darren Mcguire, Md, MD
Cardiovascular Disease — Payments: $2.0M
Cardiovascular Disease $2.0M
Dr. Peter Mccullough, Md, Mph, MD, MPH
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Robert Stoler, M.d, M.D
Cardiovascular Disease — Payments: $719,078
Cardiovascular Disease $719,078
Dr. Ann Navar, Md, Phd, MD, PHD
Cardiovascular Disease — Payments: $672,005
Cardiovascular Disease $672,005
Martin Berk, M.d, M.D
Cardiovascular Disease — Payments: $493,450
Cardiovascular Disease $493,450
James De Lemos, Md, MD
Cardiovascular Disease — Payments: $448,409
Cardiovascular Disease $448,409